More than 700 million people globally suffer from a respiratory disease | Enterprise Therapeutics | Treatment of respiratory diseases

More than 700 million
people globally suffer from
a respiratory disease

Respiratory diseases such as cystic fibrosis, asthma and COPD cause millions of deaths per year | Enterprise Therapeutics | Treatment of respiratory diseases

Respiratory diseases such as
cystic fibrosis, asthma and COPD
cause millions of deaths per year

We are developing new medicines
to treat patients with these diseases
leading to healthier and longer lives

More than 700 million people globally suffer from a respiratory disease | Enterprise Therapeutics | Treatment of respiratory diseases

More than 700 million
people globally suffer from
a respiratory disease

Respiratory diseases such as cystic fibrosis, asthma and COPD cause millions of deaths per year | Enterprise Therapeutics | Treatment of respiratory diseases

Respiratory diseases such as
cystic fibrosis, asthma and COPD
cause millions of deaths per year

We are developing new medicines to treat patients with these diseases leading to healthier and longer lives | Enterprise Therapeutics | Treatment of respiratory diseases

We are developing new medicines
to treat patients with these diseases
leading to healthier and longer lives

ENTERPRISE THERAPEUTICS

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.

In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Meet the teams

Leadership Team

Impressive drug discovery and development team with extensive experience in delivering novel and effective treatments for respiratory diseases in pharma and biotech settings.

Learn more

Board

International blend of leading corporate (Novartis Venture Fund) and more traditional venture investors (Versant, Forbion, IP Group, Epidarex, Panakes Partners) bringing individuals with a fantastic track record in Pharma and building exceptional Biotech companies.

Learn more

Advisory Board

We work closely with leading scientific experts and world-renowned physicians involved in the development of new treatments for respiratory diseases.

Learn more